4D Molecular Therapeutics
Logotype for 4D Molecular Therapeutics Inc

4D Molecular Therapeutics (FDMT) investor relations material

4D Molecular Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for 4D Molecular Therapeutics Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

4D-150 profile and phase II evidence

  • 4D-150 is designed as a continuous backbone therapy after one in-clinic intravitreal injection, potentially reducing treatment burden and helping preserve vision over time.

  • Its directed-evolution capsid enables low-dose intravitreal delivery; the payload combines aflibercept and VEGF-C RNAi to target four molecular pathways.

  • In recently diagnosed patients followed for two years, central subfield thickness was controlled and BCVA maintained; estimated treatment-burden reduction was ~90%, with roughly two-thirds needing no supplemental injections at two years.

  • At the phase III dose with topical steroid prophylaxis, mild inflammation occurred in a few patients during the first six months; all were inflammation-free from six months onward, with no significant serious or vision-threatening events described.

Phase III design and timing

  • 4FRONT-1 and 4FRONT-2 are global trials with roughly 520–530 patients each; the primary endpoint is BCVA non-inferiority, with treatment-burden reduction also assessed.

  • Trials enroll front-line patients, exclude extreme CST, require an aflibercept response after loading, and use rescue criteria based on CST and vision to protect BCVA.

  • Readouts are expected in Q2 2027 for 4FRONT-1 and H2 2027 for 4FRONT-2; each study was expanded to roughly 525–530 patients.

Market and commercial opportunity

  • The global anti-VEGF market was described as ~$16B; newer bolus therapies have delivered about 20% incremental burden reduction, versus 80%–90% seen in the phase II program.

  • Intravitreal delivery is expected to fit existing U.S. ordering, inventory, and buy-and-bill reimbursement workflows; pricing remains under consideration, with a higher price point than a single anti-VEGF dose anticipated.

  • Management cited real-world discontinuation of bolus therapy by 60% of patients within five years and 40% within two years; reducing treatment burden could also ease clinic capacity constraints.

  • Physicians and patients were described as highly receptive to a continuous, potentially injection-free backbone therapy; management sees the next 12 months as informative for the field.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next 4D Molecular Therapeutics earnings date

Logotype for 4D Molecular Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026
4D Molecular Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next 4D Molecular Therapeutics earnings date

Logotype for 4D Molecular Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

4D Molecular Therapeutics Inc. (FDMT) is a clinical-stage biotherapeutics company engaged in the development of genetic medicines using a proprietary therapeutic vector evolution platform. The company is focused on addressing serious unmet medical needs across three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Its portfolio includes genetic medicine product candidates in various stages of clinical trials. FDMT is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.